SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001144204-17-018380
Filing Date
2017-04-03
Accepted
2017-04-03 09:46:30
Documents
8
Period of Report
2016-12-31

Document Format Files

Seq Description Document Type Size
1 20-F/A v463198_20fa.htm 20-F/A 1481874
2 EXHIBIT 23.1 v463198_ex23-1.htm EX-23.1 2408
3 EXHIBIT 23.2 v463198_ex23-2.htm EX-23.2 2780
4 EXHIBIT 31.1 v463198_ex31-1.htm EX-31.1 11105
5 EXHIBIT 31.2 v463198_ex31-2.htm EX-31.2 11035
6 EXHIBIT 32.1 v463198_ex32-1.htm EX-32.1 4868
7 GRAPHIC pg31img1_20f.jpg GRAPHIC 35491
8 GRAPHIC pg97img1_20f.jpg GRAPHIC 4158
  Complete submission text file 0001144204-17-018380.txt   1569974
Mailing Address 5 HACHAROSHET ST. RAANANA L3 4365603
Business Address XTL BIOPHARMACEUTICALS LTD C/O ALSTON & BIRD LLP, 90 PARK AVENUE NEW YORK NY 10016 972 9 955 7080
XTL BIOPHARMACEUTICALS LTD (Filer) CIK: 0001023549 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3
Type: 20-F/A | Act: 34 | File No.: 001-36000 | Film No.: 17732585
SIC: 2834 Pharmaceutical Preparations